| Q90654547 | A critical appraisal of the tafazzin knockdown mouse model of Barth syndrome: what have we learned about pathogenesis and potential treatments? |
| Q61809506 | AAV9-TAZ Gene Replacement Ameliorates Cardiac TMT Proteomic Profiles in a Mouse Model of Barth Syndrome |
| Q39077752 | Barth Syndrome: Connecting Cardiolipin to Cardiomyopathy |
| Q26772690 | Barth Syndrome: From Mitochondrial Dysfunctions Associated with Aberrant Production of Reactive Oxygen Species to Pluripotent Stem Cell Studies |
| Q27936025 | Barth syndrome may be due to an acyltransferase deficiency |
| Q35003569 | Barth syndrome mutations that cause tafazzin complex lability |
| Q24632525 | Barth syndrome: an X-linked cause of fetal cardiomyopathy and stillbirth |
| Q64934202 | Barth syndrome: mechanisms and management. |
| Q36006868 | Cardiolipin and mitochondrial phosphatidylethanolamine have overlapping functions in mitochondrial fusion in Saccharomyces cerevisiae |
| Q28386643 | Cardiolipin fingerprinting of leukocytes by MALDI-TOF/MS as a screening tool for Barth syndrome |
| Q24604918 | Characterization of a transgenic short hairpin RNA-induced murine model of Tafazzin deficiency |
| Q26770152 | Combined defects in oxidative phosphorylation and fatty acid β-oxidation in mitochondrial disease |
| Q24290629 | Defective remodeling of cardiolipin and phosphatidylglycerol in Barth syndrome |
| Q28387241 | Disorders of phospholipid metabolism: an emerging class of mitochondrial disease due to defects in nuclear genes |
| Q37830368 | Disruption of mitochondrial homeostasis in organic acidurias: insights from human and animal studies |
| Q36754802 | Dysfunctional cardiac mitochondrial bioenergetic, lipidomic, and signaling in a murine model of Barth syndrome |
| Q46745637 | Endurance training ameliorates complex 3 deficiency in a mouse model of Barth syndrome. |
| Q46699248 | Functional characterization of the CgPGS1 gene reveals a link between mitochondrial phospholipid homeostasis and drug resistance in Candida glabrata |
| Q33424930 | Haematological abnormalities in mitochondrial disorders |
| Q77768830 | Infantile dilated X-linked cardiomyopathy, G4.5 mutations, altered lipids, and ultrastructural malformations of mitochondria in heart, liver, and skeletal muscle |
| Q33763830 | Loss of function of KRE5 suppresses temperature sensitivity of mutants lacking mitochondrial anionic lipids |
| Q34216280 | Metabolic cardiomyopathies |
| Q92932334 | Mitochondrial dysfunction and its role in tissue-specific cellular stress |
| Q24297605 | Mitochondrial respiratory chain supercomplexes are destabilized in Barth Syndrome patients |
| Q35264537 | Multiple presentation of mitochondrial disorders |
| Q35249958 | Mutation characterization and genotype-phenotype correlation in Barth syndrome |
| Q36127040 | Myocardial regulation of lipidomic flux by cardiolipin synthase: setting the beat for bioenergetic efficiency |
| Q42089787 | Overexpression of mitochondrial oxodicarboxylate carrier (ODC1) preserves oxidative phosphorylation in a yeast model of Barth syndrome |
| Q42369764 | Role of Cardiolipin in Mitochondrial Signaling Pathways |
| Q36709665 | Seven functional classes of Barth syndrome mutation |
| Q81446954 | TAZ encodes tafazzin, a transacylase essential for cardiolipin formation and central to the etiology of Barth syndrome. |
| Q27936928 | Taz1, an outer mitochondrial membrane protein, affects stability and assembly of inner membrane protein complexes: implications for Barth Syndrome |
| Q24651872 | The cardiolipin transacylase, tafazzin, associates with two distinct respiratory components providing insight into Barth syndrome |
| Q24300966 | The human TAZ gene complements mitochondrial dysfunction in the yeast taz1Delta mutant. Implications for Barth syndrome |
| Q37418894 | The power of yeast to model diseases of the powerhouse of the cell. |
| Q47606903 | The role of nonbilayer phospholipids in mitochondrial structure and function |
| Q34387809 | X chromosome inactivation in carriers of Barth syndrome |
| Q28139732 | X-linked cardioskeletal myopathy and neutropenia (Barth syndrome) (MIM 302060) |
| Q78254369 | X-linked cardioskeletal myopathy and neutropenia (Barth syndrome)-MIM 302060 |
| Q35687142 | Yeast as a system for modeling mitochondrial disease mechanisms and discovering therapies |